health
Blood Thinning
Adverse effectBlood thinning refers to a reduced tendency for blood to clot, which may mean bleeding takes longer to stop or bruises develop more easily. It describes a bleeding-related effect, not a diagnosis or a measure of blood pressure.
Blood Thinning is listed here as a health effect. Review the topic in a concise, neutral format.
These are research findings, not promises. Most options have little evidence, and results differ from person to person.
What can cause it
How likely each one is to cause it, most likely first.
AcupuncturepracticeUnclear
Based on 5 studies. Strongest study: a pooled analysis of several trials.
Pooled analyses of randomized trials reported mild bleeding beneath the skin and bleeding at acupuncture sites in studies involving people with several clinical conditions; these findings describe local bleeding, not a demonstrated change in blood clotting.
Open the Acupuncture pageTENS / EMS TherapypracticeUnclear
Based on one study. Strongest study: a randomized controlled trial.
An RCT involving 29 people with back pain reported bleeding.
Open the TENS / EMS Therapy pageChelation Therapy (Non-Medical)practiceUnclear
Bleeding risk differs by chelating drug: deferasirox carries a warning for gut bleeding, and EDTA infusions are often given with the blood thinner heparin.
Open the Chelation Therapy (Non-Medical) pageChagasupplementUnclear
Based on one study.
Chaga has anticoagulant properties that may increase the tendency to bleed and bruise.
Open the Chaga pageOzone TherapypracticeUnclear
Based on one study.
A pharmacology reference notes that Ozone Therapy may prolong bleeding time and reduce platelet aggregation; this is a reference-based potential effect, not a finding from a clinical trial.
Open the Ozone Therapy page
The expert view shows every study, dose protocol and source.
What can cause it
Interventions reported to bring this on5 listedHighest probability
- →PracticesAcupunctureCertaintyLowSourceClinical5 other sources
Pooled analyses of randomized trials reported mild bleeding beneath the skin and bleeding at acupuncture sites in studies involving people with several clinical conditions; these findings describe local bleeding, not a demonstrated change in blood clotting.
Who was studied
- People with a condition
- Anxiety Disorder
- Depression
- Glaucoma
- Insomnia
- Perimenopause
- Stroke
Open AcupunctureStudy result
mild subcutaneous hemorrhage
- →PracticesTENS / EMS TherapyCertaintyLowSourceClinical1 other source
An RCT involving 29 people with back pain reported bleeding.
- →PracticesChelation Therapy (Non-Medical)CertaintyLowSourceReference knowledge
Bleeding risk differs by chelating drug: deferasirox carries a warning for gut bleeding, and EDTA infusions are often given with the blood thinner heparin.
Open Chelation Therapy (Non-Medical)Study result
Some chelation drugs raise bleeding risk: deferasirox carries a warning for gut bleeding, and EDTA infusions are often given with the blood thinner heparin.
- →SupplementsChagaCertaintyLowSourceReference knowledge1 other source
Chaga has anticoagulant properties that may increase the tendency to bleed and bruise.
Open ChagaStudy result
Chaga exhibits antiplatelet activity, which may prolong bleeding time and increase bruising.
- →PracticesOzone TherapyCertaintyLowSourceReference knowledge1 other source
A pharmacology reference notes that Ozone Therapy may prolong bleeding time and reduce platelet aggregation; this is a reference-based potential effect, not a finding from a clinical trial.
Open Ozone TherapyStudy result
Ozone therapy may prolong bleeding time and reduce platelet aggregation.
How to read the evidence
Evidence tier — overall strength of the evidence for the whole compound
- StrongWell established — backed by strong, consistent human research.
- ModerateSome genuine support, but mostly from small or lower-quality studies. Promising, not proven.
- PreliminaryEarly-stage evidence — a promising hypothesis, not an established effect yet.
- LimitedVery limited evidence — treat this as a hypothesis, not proof.
- InsufficientNot enough good evidence to draw conclusions yet.
Certainty — how sure we can be that the effect is real
- Very highVery sure — strong, consistent evidence
- HighFairly sure — consistent evidence from good studies
- MediumModerately sure — new studies could change this
- LowNot sure — little or mixed evidence
- Very lowVery unsure — almost no usable evidence
Source — where the data comes from
- Meta-analysisPooled analysis of many trials — the strongest evidence
- RCTRandomized controlled trial — a strong human study design
- ClinicalA human clinical study
- Reference knowledgeFrom general health-science or pharmacology references, not a study of this exact claim
- Animal researchStudied in animals, not humans
- Community reportsAggregated user reports — anecdotal signal, not evidence
- TheoreticalMechanism-based reasoning, not yet tested
Study grade — quality of each underlying study (A best, D weakest)
- AHigh-quality — strong, consistent human trials
- BGood — solid evidence with some limitations
- CModerate — limited, small, or mixed-quality studies
- DWeak — preliminary, indirect, or animal-only
Confidence — how strongly the sources back a finding
A 0–100 score from study quality and agreement
Most supplement evidence is graded C–D. Read it as preliminary signal, not proof.
Full write-up
What is it
Blood thinning refers to a reduced tendency for blood to clot, which may mean bleeding takes longer to stop or bruises develop more easily. It describes a bleeding-related effect, not a diagnosis or a measure of blood pressure. Several interventions, including Omega-3 and Vitamin E, are associated with this effect, with the strength of evidence varying between them.
How interventions help
Blood thinning can arise through effects on platelets, which help blood clots form, or through changes that prolong bleeding time and affect coagulation. Several interventions are described in these terms, including reduced platelet aggregation, antiplatelet effects, anticoagulant properties, or coumarin-related activity. These mechanisms can present as easier bruising, increased bleeding tendency, or prolonged bleeding time rather than as a single uniform effect.
The interventions differ in how directly the finding has been observed. Omega-3 has been studied in people using a mean 3056 mg/d (RxOME3FAs) for a median 18 weeks, providing a longer-duration context for the observed outcome. Other interventions are supported by clinical reports or pharmacology references, so their descriptions may reflect reported bleeding events, known or proposed platelet effects, or potential interactions rather than a consistent outcome across all users.
The main practical overlap is with medicines that already reduce clotting or platelet activity. The information specifically identifies concern alongside anticoagulant or antiplatelet drugs, including warfarin in some reports. For some interventions, the possible effect is described as uncommon, mild, inconsistent, or uncertain, while others are associated with a clearer tendency toward bruising or prolonged bleeding. The available findings do not establish how quickly these effects begin or whether they persist after an intervention is stopped.
Choosing guidance
Choosing among these options depends on how directly the evidence reflects actual use. Clinical evidence provides a more direct basis than pharmacology references or anecdotal reports, while a review may summarize existing work without establishing that all preparations behave alike. Because health status was not specified for these entries, applicability to a particular medical condition or treatment situation is uncertain.
Amount and duration matter when interpreting the findings. Omega-3 was assessed at a substantial mean daily amount and over a sustained period, so its finding should not automatically be applied to every amount, preparation, or brief exposure. For several other options, the information describes a potential effect or interaction but does not establish a comparable dose-response pattern or time to onset. There is no consistent basis here for predicting how quickly bleeding-related effects would appear.
Readers seeking evidence from observed use may give more weight to clinical findings, while pharmacology-reference findings are better treated as plausible concerns rather than estimates of frequency. This distinction is especially important when an option is combined with anticoagulant or antiplatelet drugs, or when multiple agents with platelet or coagulation effects are used together. A comparison should account for evidence type, intended amount and duration, and whether the person’s treatment context resembles the studied population.